FDA clears myotrophin early-access program for patients with ALS

被引：0
|
作者：
不详
机构：
来源：
DRUG NEWS & PERSPECTIVES | 1996年 / 9卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：370 / 370
页数：1
相关论文
共 50 条
  • [21] RNS60 in ALS: Expanded Access Program
    Addy, Grace
    Gelevski, Dario
    Rohrer, Margot
    Scalia, Jennifer
    Yerton, Megan
    Doyle, Michael
    Parikh, Neil
    Sinani, Ervin
    Yu, Hong
    Sherman, Alexander
    Mock, Jarrad
    Kalmes, Andreas
    Hanus, Katherine
    Baecher-Allan, Clare
    Li, Zhenhua
    Wainger, Brian
    Berry, James
    Luppino, Sarah
    Paganoni, Sabrina
    Cudkowicz, Merit
    MUSCLE & NERVE, 2022, 66 : S5 - S6
  • [22] Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy
    Luigetti, Marco
    Antonini, Giovanni
    Di Paolantonio, Andrea
    Gentile, Luca
    Grandis, Marina
    Leonardi, Luca
    Lozza, Alessandro
    Manganelli, Fiore
    Mazzeo, Anna
    Mussinelli, Roberta
    My, Filomena
    Obici, Laura
    Pennisi, Elena Maria
    Romozzi, Marina
    Russo, Massimo
    Sabatelli, Mario
    Salvalaggio, Alessandro
    Tagliapietra, Matteo
    Tozza, Stefano
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (07) : 2148 - 2155
  • [23] Handel-C implementation of Early-Access Partial-Reconfiguration for Software Defined Radio
    Nezami, Kasra G.
    Stephens, Peter W.
    Walker, Stuart D.
    WCNC 2008: IEEE WIRELESS COMMUNICATIONS & NETWORKING CONFERENCE, VOLS 1-7, 2008, : 1103 - +
  • [24] The ALS Genetic Access Program: Paving the Way for Genetic Testing, Counseling and Therapy for ALS
    Rich, Kelly
    Roggenbuck, Jennifer
    Palettas, Marilly
    Schroeder, Jocelyn
    Zaleski, Christina
    Drury, Luke
    Glass, Jonathan
    NEUROLOGY, 2021, 96 (15)
  • [25] Quality of life at baseline in the international open-label early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb)
    Falcone, Alfredo
    Taieb, Julien
    Price, Timothy Jay
    Seitz, Jean Francois
    Wyrwicz, Lucjan
    Becquart, Martin
    Moreno, Shanti
    Mounedji, Nadjat
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [26] Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme
    Samalin, Ludovic
    Rotharmel, Maud
    Mekaoui, Lila
    Gaudre-Wattinne, Emeline
    Codet, Marie-Alix
    Bouju, Sophie
    Sauvaget, Anne
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2022, 26 (04) : 352 - 362
  • [27] Overview of FDA’s Expanded Access Program for Investigational Drugs
    Jonathan P. Jarow
    Peter Lurie
    Sarah Crowley Ikenberry
    Steven Lemery
    Therapeutic Innovation & Regulatory Science, 2017, 51 : 177 - 179
  • [28] Overview of FDA's Expanded Access Program for Investigational Drugs
    Jarow, Jonathan P.
    Lurie, Peter
    Ikenberry, Sarah Crowley
    Lemery, Steven
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (02) : 177 - 179
  • [29] Rilutek global early access program (EAP) reaches over 10% of amyotrophic lateral sclerosis (ALS) population
    Powe, LK
    Debove, C
    Zeisser, P
    NEUROLOGY, 1998, 50 (04) : A32 - A32
  • [30] Safety profile and tolerability of amprenavir in patients enrolled in an early access program
    Scott, T
    Garris, C
    Rogers, M
    Graham, N
    Garrett, L
    Pedneault, L
    CLINICAL THERAPEUTICS, 2001, 23 (02) : 252 - 259
12345